Hong Ma

Hong Ma

Company: CARsgen Therapeutics

Job title: Senior Vice President, Clinical Development


CLDN18.2-Targeted CAR-T Cell Therapy (CT041) in Subjects with Cancers of the Digestive System 12:30 pm

Claudin18.2 (CLDN18.2) has highly expressed in gastric, pancreatic and other GI cancers CT041 were well tolerated in subjects with CLDN18.2- positive digestive system cancers and delivers high response rate and sustained remission in the previously treated subjects with gastric cancer CycloCAR technology to co-express IL7+CCL21 may improve the efficacy and allogeneic THANK-uCAR technology could reduce…Read more

© Copyright 2022 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.